Post-Traumatic Stress Disorder: psilocybin research evidence

Why PTSD is a candidate

Trauma-related disorders involve rigid fear memories, avoidance, and disrupted meaning-making — domains where psychedelic-assisted therapy is theoretically attractive. Historically the most advanced psychedelic PTSD literature centred on MDMA; dedicated psilocybin PTSD evidence is now emerging but is not yet confirmatory.

What exists today

• Open-label Phase 2 data for single-dose 25 mg COMP360 in adults with PTSD: generally well tolerated (no serious AEs reported) with large CAPS-5 reductions and functional gains through 12 weeks.
• Mechanistic rationale around fear extinction, emotional processing, and therapeutic alliance under altered states.
• Early adjacent populations (for example demoralisation in long-term illness) that inform feasibility.
• Protocols combining psilocybin with massed cognitive processing therapy and other trauma-focused designs.

Why not "promising" yet

PSILORIS reserves promising for indications with clearer completed controlled evidence specific to that diagnosis. PTSD is therefore candidate: scientifically credible, clinically important, and still awaiting robust randomised confirmatory efficacy packages for psilocybin.

Caution

Trauma work in non-ordinary states can uncover overwhelming material. Unsupervised self-administration for PTSD is particularly high risk and is not endorsed by PSILORIS.